Safety monitoring of ophthalmic biologics: A systematic review of pre-and postmarketing safety data

Journal of Ocular Pharmacology and Therapeutics

Volumn 30, Issue 9, 2014, Pages 729-751

  Penedones, Ana ^a,b   Mendes, Diogo ^a,b   Alves, Carlos ^a,b,c   Batel Marques, Francisco ^a,b  

^a ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; PEGAPTANIB; RANIBIZUMAB; APTAMER; BIOLOGICAL PRODUCT; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ALLERGIC REACTION; BRANCH RETINAL VEIN OCCLUSION; BRONCHITIS; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL (TOPIC); CONJUNCTIVAL HEMORRHAGE; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENDOPHTHALMITIS; EYE DISEASE; EYE PAIN; GENERAL CONDITION DETERIORATION; HEADACHE; HUMAN; HYPERTENSION; IMMUNOGENICITY; IMMUNOREACTIVITY; INCIDENCE; INFLUENZA; INTRAOCULAR PRESSURE ABNORMALITY; KERATITIS; MACULAR EDEMA; MORTALITY; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PUNCTUATED KERATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRAUMATIC CATARACT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VITREOUS FLOATERS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; EYE DISEASES; PATHOLOGY; PIGMENT EPITHELIUM;

ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; BIOLOGICAL PRODUCTS; EYE DISEASES; HUMANS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL PIGMENT EPITHELIUM; THROMBOEMBOLISM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84930591988     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2013.0206     Document Type: Review

References (38)

1. Stewart, M.W. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin. Proc. 87:77-88, 2012.
2. Zampros, I., Praidou, A., Brazitikos, P., Ekonomidis, P., and Androudi, S. Antivascular endothelial growth factor agents for neovascular age-relatedmacular degeneration. J. Ophthalmol. 2012:319728, 2012.
3. Aiello, L.P., Avery, R.L., Arrigg, P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487, 1994.
4. Chakravarthy, U., Evans, J., and Rosenfeld, P.J. Age related macular degeneration. BMJ. 340:c981, 2010.
5. Bhagat, N., Grigorian, R.A., Tutela, A., and Zarbin, M.A. Diabetic macular edema: pathogenesis and treatment. Surv. Ophthalmol. 54:1-32, 2009.
6. Aref, A.A., and Scott, I.U. Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update. Adv. Ther. 28:28-39, 2011.
7. Aref, A.A., and Scott, I.U. Management of macular edema secondary to central retinal vein occlusion: an evidence-based update. Adv. Ther. 28:40-50, 2011.
8. European Medicines Agency website. Authorisation details of Macugen" (pegaptanib). Available at: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000620/human-med-000898 j sp&mid=WC0b01ac058001 d 124 (last accessed 23 Apr 2013).
9. European Medicines Agency website. Authorisation details of Lucentis" (ranibizumab). Available at: www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/medicines/000715/human-med-000890.j sp&mid=WC0b01ac058001 d 124 (last accessed 23 Apr 2013).
10. European Medicines Agency website. Authorisation details of Eylea" (aflibercept). Available at www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/medicines/002392/human-med-001598.jsp&mid=WC0b01ac058001d124 (last accessed 23 Apr 2013).
11. European Medicines Agency website. EU Summary of Product Characteristics of Macugen" (pegaptanib). 12 Aug 2013. Available at: www.ema.europa.eu/docs/en- GB/document-library/EPAR--Product-Information/human/000620/WC500026214.pdf (last accessed 26 Jan 2014).
12. European Medicines Agency website. EU Summary of Product Characteristics of Lucentis" (ranibizumab). 17 Jan 2014. Available at: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000715/WC500043546.pdf (last accessed 26 Jan 2014).
13. European Medicines Agency website. EU Summary of Product Characteristics of Eylea" (aflibercept). 04 Sep 2013. Available at: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002359/WC500135815.pdf (last accessed 26 Jan 2014).
14. Giezen, T.J., Mantel-Teeuwisse, A.K., and Leufkens, H.G Pharmacovigilance of biopharmaceuticals: challenges remain. Drug Saf. 32:811-817, 2009.
15. Ebbers, H.C., Mantel-Teewisse, A.K., Moors, E.H., et al. A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals. Drug Saf. 35:417-427, 2012.
16. Moher, D., Liberati, A., Tetzlaff, J., et al.; for The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med. 6: e1000097, 2009.
17. European Medicines Agency. Glossary (terms and abbreviations) for representatives of patients' and consumers' organisations. EMA/635046/2010 Patient Health Protection, 2010.
18. Downs, S.H., and Black, N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J. Epidemiol. Commun. Health52:377-384, 1998.
19. European Medicines Agency. Guideline on Good Phar-macovigilance Practices (GVP): Annex I-Definitions, 2012. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/05/WC500143294.pdf (last accessed 18 Jul 2014).
20. Antiplatelet Trialists' Collaboration. Collaborative overview ofrandomised trials ofantiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:81-106, 1994.
21. Ip, M.S., Scott, I.U., Brown, G.C., et al.; for the American Academy of Ophthalmology. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 115:1837-1846, 2008.
22. National Institute for Health and Clinical Excellence. Ra-nibizumab and pegaptanib for the treatment of age-related macular degeneration. NICE technology appraisal guidance 155. May 2012. Available at: http://www.nice.org.uk/guidance/ta155/resources/guidance-ranibizumab-and-pegaptanib-for-the-treatment-of-agerelated-macular-degeneration-pdf (last accessed 18 Jul 2014).
23. Scottish Medicines Consortium. SMC Advice: pegaptanib 0.3 mg, solution for intravitreal injection (Macugen"), No. 290/06. 7 August 2006. Available at: www.scottishmedicines.org.uk/files/pegaptanib-Macugen-290-06.pdf. Last accessed 18 Jul 2014.
24. Cunha-Vaz, J. The blood-retinal barrier in retinal disease. Eur. Ophthal. Rev. 3:105-108, 2009.
25. Urtti, A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 58:1131-1135, 2006.
26. Ward, B.W., and Schiller, J.S. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. Prev. Chronic Dis. 10:E65, 2013.
27. Kaplan, W., and Laing, R. Chapter 7.2: Cross-cutting issues: elderly. In: Kaplan, W., and Laing, R. eds. Priority Medicines for Europe and the World: A Public Health Approach to Innovation. World Health Organization; 2004; p. 90-91.
28. Routledge, P.A., O'Mahony, M.S., and Woodhouse, K.W. Adverse drug reactions in elderly patients. Br. J. Clin. Pharmacol. 57:121-126, 2004.
29. Go, A.S. Mozzaffarian, D., Roger, V.L., et al.; for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2013 Update: A Report From the American Heart Association. Circulation 127:e841, 2013.
30. Enseleit, F., Michels, S., and Ruschitzka, F. Anti-VEGF therapies and blood pressure: more than meets the eye. Curr. Hypertens. Rep. 12:33-38, 2010.
31. Hyman, L., Schachat, A.P. He, Q., and Leske, M.C. Hypertension, cardiovascular diseases, and age-related macular degeneration. Arch. Ophthalmol. 118:351-358, 2000.
32. European network for Health Technology Assessment. Endpoints used in relative effectiveness assessment of pharmaceuticals-safety. EUnetHTA JA1 WP5 Methodology Guidelines, 2013. Available at: http://5026.fedimbo.belgium.be/sites/5026.fedimbo.belgium.be/files/Safety.pdf (last accessed 18 Jul 2014).
33. Singh, S., and Loke, Y.K. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 13:138, 2012.
34. Stricker, B.H., and Psaty, BM. Detection, verification, and quantification of adverse drug reactions. BMJ. 329:44-47, 2004.
35. Strom, B.L. Study designs available for pharmacoepidemiology studies. In: Strom, B.L., and Kimmel, S.E., eds. Textbook of Pharmacoepidemiology. West Sussex, John Wiley & Sons, Ltd.; 2006, p. 13-24.
36. Gutfleisch, M., Heimes, B., Schumacher, M., et al. Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD. Eye (Lond). 25:1181-1186, 2011.
37. Introini, U., Torres Gimeno, A., Scotti, F., et al. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence. Graefes Arch. Clin. Exp. Ophthalmol. 250:1283-1292, 2012.
38. Pfizer. Direct Healthcare Professional Communication on Macugen" (pegaptanib sodium); Risk of serious increase in intraocular pressure with the injection of an excess volume of Macugen intravitreally. Available at: www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con199564.pdf. Last accessed 18 Jul 2014.